Adjuvants in influenza vaccines

Vaccine

Volumn 30, Issue 52, 2012, Pages 7658-7661

  Tetsutani, Kohhei ^a   Ishii, Ken J ^a  

^a NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

Author keywords

Influenza vaccine; Vaccine adjuvant

Indexed keywords

AS 03; GENOMIC RNA; INFLUENZA VACCINE; MIFAMURTIDE; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; UNCLASSIFIED DRUG;

ANTIBODY TITER; CELLULAR IMMUNITY; DRUG TOLERABILITY; HUMAN; IMMUNOGENICITY; INFLUENZA; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SEROCONVERSION; VIRION; VIRUS PARTICLE;

ADJUVANTS, IMMUNOLOGIC; ALPHA-TOCOPHEROL; ALUM COMPOUNDS; DRUG COMBINATIONS; HUMANS; INFLUENZA VACCINES; POLYSORBATES; SQUALENE; VACCINES, INACTIVATED;

EID: 84870533931     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.10.007     Document Type: Review

References (39)

1. OECD Health at a glance 2011: OECD indicators 2011, p. 125.
2. Harrison W.T. Some observations on the use of alum precipitated diphtheria toxoid. Am J Public Health Nations Health 1935, 25:298-300.
3. ®; Fluenz™): a review of its use in the prevention of seasonal influenza in children and adults. Drugs 2011, 71:1591-1622.
4. Simon J.K., Ramirez K., Cuberos L., Campbell J.D., Viret J.F., Muñoz A., et al. Mucosal IgA responses in healthy adult volunteers following intranasal spray delivery of a live attenuated measles vaccine. Clin Vaccine Immunol 2011, 18:355-361.
5. Laurent P.E., Bourhy H., Fantino M. Safety and efficacy of novel dermal and epidermal microneedle delivery systems for rabies vaccination in healthy adults. Vaccine 2010, 28:5850-5856.
6. Van Damme P., Oosterhuis-Kafeja F., Van der Wielen M., Almagor Y., Sharon O., Levin Y. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine 2009, 27:454-459.
7. Giaquinto C., Dominiak-Felden G., Van Damme P., Myint T.T., Maldonado Y.A., Spoulou V., et al. Summary of effectiveness and impact of rotavirus vaccination with the oral pentavalent rotavirus vaccine: a systematic review of the experience in industrialized countries. Hum Vaccine 2011, 7:734-748.
8. World Health Organization. Clinical trials of influenza vaccine. http://www.who.int/vaccine_research/diseases/influenza/flu_trials_tables/en/.
9. Ehrlich H.J., Mueller M., Oh H.M., Tambyah P.A., Joukhadar C., Montomoli E., et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 2008, 358:2573-2584.
10. Leroux-Roels I., Bernhard R., Gérard P., Dramé M., Hanon E., Leroux-Roels G. Broad clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS ONE 2008, 3:e1665.
11. Leroux-Roels I., Roman F., Forgus S., Maes C., De Boever F., Drame M., et al. Priming with AS03-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination; an open non-randomized extension of a double-blind randomized primary study. Vaccine 2010, 28:849-857.
12. Bresson J.L., Perronne C., Launay O., Gerdil C., Saville M., Wood J., et al. Safety and immunogenicity of an inactivated split-virion influenza/Vietnam/1194/2004(H5N1) vaccine: phase I randomized trial. Lancet 2006, 367:1657-1664.
13. Leroux-Roels I., Van der Wielen M., Kafeja F., Vandermeulen C., Lazarus R., Snape M.D., et al. Humoral and cellular immune responses to split-virion H5N1 influenza vaccine in young and elderly adults. Vaccine 2009, 27:6918-6925.
14. Brady R.C., Treanor J.J., Atmar R.L., Keitel W.A., Edelman R., Chen W.H., et al. Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults. Vaccine 2009, 27:5091-5095.
15. Keitel W.A., Campbell J.D., Treanor J.J., Walter E.B., Patel S.M., He F., et al. Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial. J Infect Dis 2008, 198:1309-1316.
16. Stephenson I., Bugarini R., Nicholson K.G., Podda A., Wood J.M., Zambon M.C., et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/duck/Singapore97(H5N3) vaccine: a potential priming strategy. J Infect Dis 2005, 191:1210-1215.
17. Galli G., Hancock K., Hoschler K., DeVos J., Praus M., Bardelli M., et al. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci USA 2009, 106:7962-7967.
18. Atmar R.L., Keitel W.A., Patel S.M., Katz J.M., She D., El Sahly H., et al. Safety and immunogenicity of nonadjuvanted and MF59-aduvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis 2006, 43:1135-1142.
19. Clark T.W., Pareek M., Hoschler K., Dillon H., Nicholson K.G., Groth N., et al. Trial of 2009 influenza A(H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009, 361:2424-2435.
20. Cox R.J., Pedersen G., Madhun A.S., Svindland S., Sævik M., Breakwell L., et al. Evaluation of a virosomal H5N1 vaccine formulated with Matrix M adjuvant in a phase I clinical trial. Vaccine 2011, 29:8049-8059.
21. Saenger R., Schussmann K.M., Preusche A., Kuehl H.O., Riemer N., Reiners B., et al. Immunogenicity and persistence of response to an alum-adjuvanted monovalente (H9N2) whole virus influenza vaccine in healthy adults aged 60 years and older. Presentation in International conference on influenza vaccines for the world-IVW2006 2006.
22. Hehme N.W. GSK's pandemic vaccine development. Presentation in 3rd meeting on evaluation of pandemic influenza vaccines in clinical trials 2007.
23. Kanazashi S., Yagi Y., Komatsu F., Ninomiya Y. UMN-0501 Pandemic influenza recombinant HA vaccine phase I/II study in Japan. Presentation in WHO meeting 2009.
24. Cox M. Pandemic influenza vaccine clinical trial abstract minimum information.
25. Vesikari T., Groth N., Karvonen A., Borkowski A., Pellegrini M. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. Vaccine 2009, 27:6291-6295.
26. Durando P., Fenoglio D., Boschini A., Ansaldi F., Icardi G., Sticchi L., et al. Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults. Clin Vaccine Immunol 2008, 15:253-259.
27. Vesikari T., Knuf M., Wutzler P., Karvonen A., Kieninger-Baum D., Schmitt H.J., et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med 2011, 365:1406-1416.
28. The European Agency for the Evaluation of Medical Products Note for guidance on harmonization of requirements for influenza vaccines (CPMP/BWP/214/96) 1997.
29. European Medicines Agency Guideline on influenza vaccines prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier context (CHMP/VWP/263499/2006) 2007.
30. Heineman T.C., Clements-Mann M.L., Poland G.A., Jacobson R.M., Izu A.E., Sakamoto D., et al. A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. Vaccine 1999, 17:2769-2778.
31. Iob A., Brianti G., Zamparo E., Gallo T. Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy. Epidemiol Infect 2005, 133:687-693.
32. Geeraedts F., Goutagny N., Hornung V., Severa M., de Haan A., Pool J., et al. Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signaling. PLoS Pathog 2008, 4:e1000138.
33. Koyama S., Aoshi T., Tanimoto T., Kumagai Y., Kobiyama K., Tougan T., et al. Plasmacytoid dendritic cells delineate immunogenicity of influenza vaccine subtypes. Sci Transl Med 2010, 2:25.
34. Clifford H.D., Yerkovich S.T., Khoo S.K., Zhang G., Upham J., Le Souëf P.N., et al. Toll-like receptor 7 and 8 polymorphisms: associations with functional effects and cellular and antibody responses to measles virus and vaccine. Immunogenetics 2012, 64:219-228.
35. Caskey M., Lefebvre F., Filali-Mouhim A., Cameron M.J., Goulet J.P., Haddad E.K., et al. Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans. J Exp Med 2011, 208:2357-2366.
36. Mosca F., Tritto E., Muzzi A., Monaci E., Bagnoli F., Iavarone C., et al. Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci U S A 2008, 105:10501-10506.
37. Calabro S., Tortoli M., Baudner B.C., Pacitto A., Cortese M., O'Hagan D.T., et al. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 2011, 29:1812-1823.
38. Lu X., Tian Y., Zhao Q., Jin T., Xiao S., Fan X. Integrated metabonomics analysis of the size-response relationship of silica nanoparticles-induced toxicity in mice. Nanotechnology 2011, 22:055101.
39. Fox C.B., Baldwin S.L., Duthie M.S., Reed S.G., Vedvick T.S. Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions. Vaccine 2011, 29:9563-9572.